These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24351500)

  • 41. The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
    Kim TY
    Korean J Hepatol; 2012 Mar; 18(1):29-31. PubMed ID: 22511900
    [No Abstract]   [Full Text] [Related]  

  • 42. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
    Hadziyannis SJ; Sevastianos V
    Aliment Pharmacol Ther; 2013 Feb; 37(4):491. PubMed ID: 23336678
    [No Abstract]   [Full Text] [Related]  

  • 43. [Chronic C virus infection management].
    García González N; Prieto Valtueña J
    Rev Clin Esp; 2003 Sep; 203(9):443-4. PubMed ID: 14563259
    [No Abstract]   [Full Text] [Related]  

  • 44. Hepatitis in 2010: the dawn of a new era in HCV therapy.
    Ciesek S; Manns MP
    Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):69-71. PubMed ID: 21293503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.
    Heo J
    Korean J Hepatol; 2011 Sep; 17(3):180-2. PubMed ID: 22102383
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
    Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ
    Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting].
    Saiz de la Hoya-Zamácola P; Marco-Mouriño A; Clemente-Ricote G; Portilla-Sogorb J; Boix-Martínez V; Núñez-Martínez O; Reus-Bañuls S; Teixidó i Pérez N
    Enferm Infecc Microbiol Clin; 2006 Nov; 24(9):568-75. PubMed ID: 17125677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protease inhibitors for hepatitis C: economic implications.
    Turner SJ; Brown J; Paladino JA
    Pharmacoeconomics; 2013 Sep; 31(9):739-51. PubMed ID: 23839698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of hepatitis C virus treatment between incarcerated and community patients.
    Rice JP; Burnett D; Tsotsis H; Lindstrom MJ; Cornett DD; Voermans P; Sawyer J; Striker R; Lucey MR
    Hepatology; 2012 Oct; 56(4):1252-60. PubMed ID: 22505121
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.
    Perry CM
    Drugs; 2012 Mar; 72(5):619-41. PubMed ID: 22439668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review.
    Chou R; Hartung D; Rahman B; Wasson N; Cottrell EB; Fu R
    Ann Intern Med; 2013 Jan; 158(2):114-23. PubMed ID: 23437439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Henke H; Schmiegel W; Brechmann T; Voigt E; Griga T
    J Clin Gastroenterol; 2004 Mar; 38(3):301-3. PubMed ID: 15128086
    [No Abstract]   [Full Text] [Related]  

  • 54. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive improvement after HCV eradication: Extending the benefits.
    Bajaj JS; Forton DM
    Hepatology; 2013 Aug; 58(2):480-2. PubMed ID: 23696270
    [No Abstract]   [Full Text] [Related]  

  • 56. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

  • 57. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
    Cooper C; Lester R; Thorlund K; Druyts E; El Khoury AC; Yaya S; Mills EJ
    QJM; 2013 Feb; 106(2):153-63. PubMed ID: 23159839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands.
    Mutimer D
    Gut; 2015 Feb; 64(2):190-1. PubMed ID: 24861270
    [No Abstract]   [Full Text] [Related]  

  • 59. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
    J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.